Identifying ITGB2 as a Potential Prognostic Biomarker in Ovarian Cancer. 2023

Chanyuan Li, and Ting Deng, and Junya Cao, and Yun Zhou, and Xiaolin Luo, and Yanling Feng, and He Huang, and Jihong Liu
Cancer Center, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, China.

Epithelial ovarian cancer is by far the most lethal gynecological malignancy. The exploration of promising immunomarkers to predict prognosis in ovarian cancer patients remains challenging. In our research, we carried out an integrated bioinformatic analysis of genome expressions and their immune characteristics in the ovarian cancer microenvironment with validation in different experiments. We filtrated 332 differentially expressed genes with 10 upregulated hub genes from the Gene Expression Omnibus database. These genes were closely related to ovarian tumorigenesis. Subsequently, the survival and immune infiltration analysis demonstrated that the upregulation of five candidate genes, ITGB2, VEGFA, CLDN4, OCLN, and SPP1, were correlated with an unfavorable clinical outcome and increased immune cell infiltration in ovarian cancer. Of these genes, ITGB2 tended to be the gene most correlated with various immune cell infiltrations and had a strong correlation with significant M2 macrophages infiltration (r = 0.707, p = 4.71 × 10-39), while it had a moderate correlation with CD4+/CD8+ T cells and B cells. This characteristic explains why the high expression of ITGB2 was accompanied by immune activation but did not reverse carcinogenesis. Additionally, we confirmed that ITGB2 was over-expressed in ovarian cancer tissues and was mainly located in cytoplasm, detected by Western blotting and the immunohistochemical method. In summary, ITGB2 may serve as a prognostic immunomarker for ovarian cancer patients.

UI MeSH Term Description Entries

Related Publications

Chanyuan Li, and Ting Deng, and Junya Cao, and Yun Zhou, and Xiaolin Luo, and Yanling Feng, and He Huang, and Jihong Liu
February 2022, Diagnostics (Basel, Switzerland),
Chanyuan Li, and Ting Deng, and Junya Cao, and Yun Zhou, and Xiaolin Luo, and Yanling Feng, and He Huang, and Jihong Liu
October 2023, ACS nano,
Chanyuan Li, and Ting Deng, and Junya Cao, and Yun Zhou, and Xiaolin Luo, and Yanling Feng, and He Huang, and Jihong Liu
October 2023, Biomedicines,
Chanyuan Li, and Ting Deng, and Junya Cao, and Yun Zhou, and Xiaolin Luo, and Yanling Feng, and He Huang, and Jihong Liu
October 2013, The Journal of clinical investigation,
Chanyuan Li, and Ting Deng, and Junya Cao, and Yun Zhou, and Xiaolin Luo, and Yanling Feng, and He Huang, and Jihong Liu
December 2020, Cancer biology & therapy,
Chanyuan Li, and Ting Deng, and Junya Cao, and Yun Zhou, and Xiaolin Luo, and Yanling Feng, and He Huang, and Jihong Liu
January 2020, PloS one,
Chanyuan Li, and Ting Deng, and Junya Cao, and Yun Zhou, and Xiaolin Luo, and Yanling Feng, and He Huang, and Jihong Liu
January 2023, PeerJ,
Chanyuan Li, and Ting Deng, and Junya Cao, and Yun Zhou, and Xiaolin Luo, and Yanling Feng, and He Huang, and Jihong Liu
April 2002, JAMA,
Chanyuan Li, and Ting Deng, and Junya Cao, and Yun Zhou, and Xiaolin Luo, and Yanling Feng, and He Huang, and Jihong Liu
March 2024, Gynecologic oncology,
Chanyuan Li, and Ting Deng, and Junya Cao, and Yun Zhou, and Xiaolin Luo, and Yanling Feng, and He Huang, and Jihong Liu
September 2022, Cancer biotherapy & radiopharmaceuticals,
Copied contents to your clipboard!